Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences
A copy of the presentation materials will be made available on the company website (www.sorrentotherapeutics.com).
|Date:||Thursday, February 28|
|Time:||3:30pm Eastern Time|
|Location:||Lotte New York Palace Hotel|
|Date:||Wednesday, March 20|
|Time:||2:45pm Eastern Time|
|Location:||Westin Grand Central Hotel, Ambassador Room|
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. Resiniferatoxin is completing a phase IB trial in terminal cancer patients and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the
For more information visit www.sorrentotherapeutics.com.
LifeSci Advisors, LLC
Source: Sorrento Therapeutics, Inc.